Frontage Laboratories received $10 million in growth capital from a group of investors led by Baird Capital Partners Asia (BCPA), the first investment made by the China-centered initiative of Baird Private Equity. The new capital is targeted at enlarging the company’s China operations with the goal of creating a world-class US-China CRO. More details...